A Phase I Pharmacologic Study of Necitumumab (imc-11f8), a Fully Human Igg1 Monoclonal Antibody the Alk/ros1 Inhibitor Pf-06463922 Overcomes Primary Resistance to Crizotinib in Alk-driven Neuroblastoma
暂无分享,去创建一个
H. Zou | Y. Mossé | M. Lemmon | T. Smeal | Yimei Li | N. Lee | Jin H. Park | K. Szigety | R. Sano | K. Krytska | Nicole R. Infarinato | H. Ryles | Andreas G. Bader | Matthew Winkler | David Brown